GMP risk model advisory committee
Executive Summary
FDA development of a risk model for good manufacturing practices will be discussed by the Manufacturing Subcommittee of the Pharmaceutical Science Advisory Committee July 20. The subcommittee will hear updates on manufacturing science and quality by design efforts. The subcommittee last discussed the topic at its September 2003 meeting (1"The Pink Sheet" Sept,. 29, 2003, p. 40). On July 21, the subcommittee will consider a quality system approach for the production of investigational new drugs and provide comments on manufacturing science and risk-based questions for new drug application chemistry, manufacturing & controls review processes. The meeting will be held at CDER's advisory committee conference room at 5630 Fishers Lane in Rockville, Md. beginning at 8:30 a.m. [To 2watch a webcast or order a video/DVD of this meeting, go to FDAAdvisoryCommittee.com.]...
You may also be interested in...
FDA “Quality By Design” Initially Focuses On Post-Approval Manufacturing
FDA will focus initially on the post-approval regulatory pathway as the most likely starting point for firms instituting "quality by design" manufacturing
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.